Richard Wenstrup

Epic Sciences (United States) — United States

Medicine · Health Sciences

57h-index17.2kcitations271works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(80), Connective tissue disorders research(51), BRCA gene mutations in cancer(38), Cancer Genomics and Diagnostics(27), Genetic factors in colorectal cancer(24)

Publications271 total

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2025Open Access
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer
JCI Insight·2025Open Access
643eP The association of circulating tumor cells with body mass index, body composition and blood biomarkers in patients with newly diagnosed metastatic breast cancer
Annals of Oncology·2025
Quantum Cognition Machine Learning for Forecasting Chromosomal Instability
2025Open Access
Quantum Cognition Machine Learning for Forecasting Chromosomal Instability
arXiv (Cornell University)·2025Open Access
Abstract 1145: Morphological evaluation of chromosomal instability in circulating tumor cells and prediction of taxane resistance in metastatic prostate cancer: a prespecified sub-analysis of the CARD trial
Cancer Research·2025
489P Liquid biopsy with combination of cell & cell-free analysis identifies HER2-expression in patients with metastatic breast cancer
Annals of Oncology·2023Open Access
1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Annals of Oncology·2023Open Access
Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2023Open Access
Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2023Open Access
Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2023Open Access
Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2023Open Access
Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
2023Open Access
page 1 of 14Next →

Frequent Co-authors

Jane B. Florer(8), Anne‐Renee Hartman(6), Brian Allen(5), David E. Birk(5), Sapna Syngal(5), Benjamin B. Roa(5), Lynn Anne Burbidge(5), Cynthia Frye(4), Rajesh Kaldate(4), Jennifer Saam(3), Kelsey Moyes(3), Anne De Paepe(3), Beat Steinmann(3), Christopher Arnell(3), John Kidd(3), Nanda Singh(3), Inna Chervoneva(3), Dmitry Pruss(3), Karla R. Bowles(3), Kirsten M. Timms(3)